Table 7 Clinical adverse experiences considered to be related to study drug†that occurred at an incidence rate of ≥0.5% in any group
From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
| Â | Sitagliptin 100 mg n (%) (N = 3415) | Non-Exposed n (%) (N = 2724) | Difference between Sitagliptin and Non-Exposed % (95% CI)* |
|---|---|---|---|
Abdominal Pain Upper | 18 (0.5) | 11 (0.4) | 0.1 (-0.2, 0.5) |
Constipation | 25 (0.7) | 13 (0.5) | 0.3 (-0.2, 0.7) |
Diarrhea | 42 (1.2) | 45 (1.7) | -0.4 (-1.1, 0.2) |
Dyspepsia | 19 (0.6) | 13 (0.5) | 0.1 (-0.3, 0.4) |
Nausea | 33 (1.0) | 31 (1.1) | -0.2 (-0.7, 0.3) |
Fatigue | 19 (0.6) | 20 (0.7) | -0.2 (-0.6, 0.2) |
Peripheral Edema | 11 (0.3) | 16 (0.6) | -0.3 (-0.7, 0.1) |
Blood Glucose | 6 (0.2) | 16 (0.6) | -0.4 (-0.8, -0.1) |
Decreased | Â | Â | Â |
Hypoglycemia‡ | 87 (2.5) | 203 (7.5) | -4.9 (-6.1, -3.8) |
Dizziness | 17 (0.5) | 13 (0.5) | 0.0 (-0.4, 0.4) |
Headache | 37 (1.1) | 29 (1.1) | 0.0 (-0.5, 0.5) |